(Bloomberg Opinion) -- It’s good to come in first in drug development, though it’s not always a guarantee of long-term commercial success. Short market monopolies can be highly lucrative. Investors are rewarding Intercept Pharmaceuticals Inc. on that basis. The New York-based drugmaker announced Tuesday that its medicine Ocaliva is the...